Lupin Spins Out Oncology Assets to New Venture Kaveri Therapeutics
Mumbai-based pharmaceutical giant Lupin has divested two key oncology programs to the newly formed U.S. clinical-stage firm Kaveri Therapeutics. By transferring the LNP7457 and LNP8701 assets into an independent entity, Lupin aims to accelerate global clinical development while retaining a significant equity stake in the startup.























:format(jpg)/f.elconfidencial.com%2Foriginal%2F08d%2F58d%2F796%2F08d58d79656e645b90cf331561961452.jpg)